Sep 21, 2021 / 02:00PM GMT
Michael Hencke - Biogen Inc. - Director of IR
Good morning, everyone. Thank you for joining us for our Investor R&D Day. I'm Mike Hencke in Investor Relations.
Before we begin, I would like to point out that we will be making forward-looking statements, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. I encourage you to consult the risk factors in our SEC filings for additional detail.
We're excited to share with you today the progress we are making in R&D across neuroscience. Today's program will include multiple live presentations followed by a live Q&A session. The slides presented today can be found on the Investor section of our website.
We'll begin with presentations from our Chief Executive Officer, Michel Vounatsos; and Al Sandrock, our Head of R&D. You will then hear from a number of other senior leaders across therapeutic areas. And we will conclude with the Q&A session. We will take a short break at approximately 11:30 a.m. And we aim to conclude today's event at
Biogen Inc Investor Day Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot